Antibody responses in parvovirus B19 infected patients

Pathologie Biologie

Volumn 50, Issue 5, 2002, Pages 326-331

  Modrow, Susanne ^a   Dorsch, Simone ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

IgG; IgG antibodies; IgM; Parvovirus B19; Persisting viremia

Indexed keywords

ANTIBODY; CAPSID PROTEIN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN VP1; PROTEIN VP2; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY RESPONSE; APLASTIC ANEMIA; ARTHRITIS; ARTICLE; BONE MARROW; CLINICAL FEATURE; DISEASE COURSE; ERYTHEMA INFECTIOSUM; FETUS HYDROPS; GRANULOCYTOPENIA; HEPATITIS; HUMAN; LIVER; MYOCARDITIS; PARVOVIRUS; PERSISTENT VIRUS INFECTION; PROTECTION; SPONTANEOUS ABORTION; SYNOVIAL FLUID; THROMBOCYTOPENIA; VIRUS CAPSID; VIRUS INFECTION; VIRUS STRAIN;

EID: 0036088935     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(02)00302-4     Document Type: Article

References (59)

1. Parvovirus-like particles in human sera
2. Human parvovirus, the cause of erythema infectiosum (fifth disease)?
3. Polyarteritis nodosa and parvovirus B19 infection
4. Rheumatologic manifestations of human parvovirus B 19 infection in adults. Initial two-year clinical experience
5. Human parvovirus-associated arthritis: A clinical and laboratory description
6. Chronic autoimmune thrombopenia/neutropenia in a boy with persistent parvovirus B19 infection
7. Human parvovirus B19 and arthritis
8. Another viral candidate
9. Immediate and long term outcome of human parvovirus B19 infection in pregnancy
10. Human parvovirus infection in homozygous sickle cell disease
11. Human parvovirus B19 in intrauterine fetal death
12. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): A treatable cause of anemia in AIDS
13. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy
14. Immune response to B19 parvovirus and an antibody defect in persistent viral infection
15. Chronic bone marrow failure due to persistent B19 parvovirus infection
16. Candidate recombinant vaccine for human B19 parvovirus
17. Most of the VP1 unique region of B19 parvovirus is on the capsid surface
18. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface
19. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions
20. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
21. Sequence variability among different parvovirus B19 isolates
22. Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue
23. The VP1-unique region of parvovirus B19: Amino acid variability and antigenic stability
24. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19
25. Erythrocyte P antigen: Cellular receptor for B19 parvovirus
26. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins
27. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions
28. Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19
29. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins
30. A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response
31. Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies
32. Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: Correlation to a major surface region on the native virus particle
33. Characterization of cis-acting and NS1 protein-responsive elements in the p6 promoter of parvovirus B 19
34. Cellular transcription factors that interact with p6 promoter elements of parvovirus B19
35. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression
36. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells
37. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19
38. NS1-protein of parvovirus B19 interacts directly with DNA sequences of the p6-promoter and with cellular transcription factors Sp1/Sp3
39. Antibodies to parvovirus B19 NS-1 protein in infected individuals
40. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay
41. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the VP1-unique region of VP1
42. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans
43. Persistent parvovirus B19 infections in immunocompromised children
44. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: Use of intravenous immunoglobulin - A report of eight patients
45. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia
46. Parvovirus B19 as a cause of chronic anemia in rhabdomyosarcoma
47. Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient
48. Chronic parvovirus infection in a presumably immunologically healthy woman
49. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin
50. Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection
51. Persistent infection of human parvovirus B19 in a normal subject
52. Lymphoproliferative responses after infection with human parvovirus B19
53. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: Implications for pathogenesis
54. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence
55. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection
56. Prevalence of NS1-specific antibodies in patients infected with parvovirus B19 and in pregnant women
57. There is no association between polymyalgia rheumatica and acute parvovirus B19 infection
58. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells
59. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy